JP2016510768A5 - - Google Patents

Download PDF

Info

Publication number
JP2016510768A5
JP2016510768A5 JP2015561831A JP2015561831A JP2016510768A5 JP 2016510768 A5 JP2016510768 A5 JP 2016510768A5 JP 2015561831 A JP2015561831 A JP 2015561831A JP 2015561831 A JP2015561831 A JP 2015561831A JP 2016510768 A5 JP2016510768 A5 JP 2016510768A5
Authority
JP
Japan
Prior art keywords
crystalline form
form suc
suc
impurities
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015561831A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510768A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2014/000272 external-priority patent/WO2014138812A1/en
Publication of JP2016510768A publication Critical patent/JP2016510768A/ja
Publication of JP2016510768A5 publication Critical patent/JP2016510768A5/ja
Pending legal-status Critical Current

Links

JP2015561831A 2013-03-15 2014-03-14 抗不安化合物の塩、共結晶及び多形 Pending JP2016510768A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361798926P 2013-03-15 2013-03-15
US61/798,926 2013-03-15
PCT/AU2014/000272 WO2014138812A1 (en) 2013-03-15 2014-03-14 Salts, co-crystals, and polymorphs of an anxiolytic compound

Publications (2)

Publication Number Publication Date
JP2016510768A JP2016510768A (ja) 2016-04-11
JP2016510768A5 true JP2016510768A5 (enExample) 2017-04-20

Family

ID=51535621

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015561831A Pending JP2016510768A (ja) 2013-03-15 2014-03-14 抗不安化合物の塩、共結晶及び多形

Country Status (9)

Country Link
US (2) US9745296B2 (enExample)
EP (1) EP2970247A4 (enExample)
JP (1) JP2016510768A (enExample)
CN (1) CN105492440A (enExample)
AU (2) AU2014231722B2 (enExample)
CA (1) CA2905570A1 (enExample)
HK (1) HK1220191A1 (enExample)
MX (1) MX2015013059A (enExample)
WO (1) WO2014138812A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6688434B2 (en) 2002-02-22 2004-02-10 Ecolab Inc. Conveyor and lubricating apparatus, lubricant dispensing device, and method for applying lubricant to conveyor
CN105541701A (zh) * 2015-12-11 2016-05-04 吉林大学珠海学院 以顺丁烯二酸为前驱体的去铁酮药物共晶及其制备方法
TWI863630B (zh) * 2015-12-15 2024-11-21 以色列商諾威股份有限公司 用於測量圖案化半導體結構之特性的系統
WO2019109150A1 (en) * 2017-12-07 2019-06-13 Bionomics Limited Methods of treating agitation
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
WO2021056048A1 (en) * 2019-09-23 2021-04-01 Bionomics Limited Therapeutic formulations and uses thereof
AU2023201463A1 (en) * 2023-03-08 2024-09-26 Bionomics Limited Method of treating social anxiety disorder
JPWO2025033432A1 (enExample) * 2023-08-08 2025-02-13

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2535803A1 (en) * 2003-08-21 2005-03-03 Transoral Pharmaceuticals, Inc. Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof
ES2399071T3 (es) 2006-10-16 2013-03-25 Bionomics Limited Nuevos compuestos ansiolíticos
DE102006060598A1 (de) * 2006-12-21 2008-06-26 Merck Patent Gmbh Tetrahydrobenzoisoxazole
GB0706044D0 (en) * 2007-03-28 2007-05-09 Syngenta Ltd C0-Crystals
CN102770434A (zh) * 2009-12-03 2012-11-07 阿斯利康(瑞典)有限公司 三唑并[4,5-d]嘧啶血小板聚集抑制剂的共晶体
WO2012116410A1 (en) 2011-03-02 2012-09-07 Bionomics Limited Methods of treating a disease or condition of the central nervous system
JP6055817B2 (ja) 2011-05-12 2016-12-27 バイオノミックス リミテッド ナフチリジンの調製方法
AU2013204159B2 (en) * 2013-03-15 2015-05-07 Bionomics Limited A Crystalline Form of an Anxiolytic Compound

Similar Documents

Publication Publication Date Title
JP2021530565A5 (enExample)
JP2018115191A5 (enExample)
JP2010516681A5 (enExample)
JP2013032389A5 (enExample)
JP2012513416A5 (enExample)
JP2013542261A5 (enExample)
JP2016190843A5 (enExample)
JP2016537346A5 (enExample)
JP2020502092A5 (enExample)
EP4643945A3 (en) Neuroactive steroids and methods of use thereof
JP2014501282A5 (enExample)
JP2015078230A5 (enExample)
SI2956452T1 (en) Heterocyclic amides as kinase inhibitors
JP2012176975A5 (enExample)
JP2011528658A5 (enExample)
JP2017528506A5 (enExample)
JP2015516427A5 (enExample)
JP2014530818A5 (enExample)
JP2020502224A5 (enExample)
JP2011088926A5 (enExample)
JP2016529315A5 (enExample)
JP2016510767A5 (enExample)
RU2019105794A (ru) Кристаллогидрат соединения (2s, 3r) -изопропил 2 - (((2- (1,5-диметил-6-оксо-1,6-дигидропиридин-3-ил) -1 - ((тетрагидро-2h-пиран) -4-ил) метил) -1h-бензо [d] имидазол-5-ил) метил) амино) -3-гидроксибутаноат эдисилат
JP2016537326A5 (enExample)
RU2012136148A (ru) Новая кристаллическая форма производного циклопропилбензамида